High-density lipoprotein therapy: is there hope?

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Traditional lipid management focuses on LDL-C reduction, yet many patients still experience cardiovascular events.
• Low HDL-C levels (<40 mg/dL) are independently associated with increased cardiovascular disease (CVD) risk.
• Low HDL-C is a component of the metabolic syndrome and often observed in insulin resistance states.

Purpose of the Study:

• To review the role of high-density lipoprotein cholesterol (HDL-C) in cardiovascular disease (CVD).
• To discuss current and emerging therapeutic strategies for managing low HDL-C levels.
• To evaluate the efficacy of various agents in raising HDL-C and reducing CVD risk.

Main Methods:

• Review of epidemiological studies and clinical trial data on lipid abnormalities and CVD.
• Analysis of current guidelines and treatment approaches for low HDL-C.
• Discussion of pharmacologic options, including statins, fibrates, niacin, and CETP inhibitors.

Main Results:

• Low HDL-C is prevalent in patients with CVD and associated with higher cardiovascular risk.
• Lifestyle modifications are the first-line approach for increasing HDL-C.
• Niacin is the most potent available HDL-C-raising therapy; CETP inhibitors are under investigation.

Conclusions:

• Despite LDL-C control, low HDL-C remains a significant CVD risk factor.
• Pharmacologic intervention to raise HDL-C, particularly with niacin, should be considered in select patients.
• Novel therapies like CETP inhibitors may offer future options for managing dyslipidemia and reducing CVD events.